Published in Eur Heart J on May 04, 2005
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol (2005) 1.61
Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance. Diabetes (2011) 1.29
Genetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts. Diabetes (2012) 1.18
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol (2007) 1.18
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol (2012) 1.10
"The metabolic syndrome... is dead": these reports are an exaggeration. Cardiovasc Diabetol (2011) 1.08
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol (2012) 0.98
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol (2006) 0.95
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol (2009) 0.95
Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol (2011) 0.91
Antidiabetic action of bezafibrate in a large observational database. Diabetes Care (2009) 0.90
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol (2010) 0.89
Ocular Effects of Niacin: A Review of the Literature. Med Hypothesis Discov Innov Ophthalmol (2015) 0.88
Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats. Int J Pept (2012) 0.83
Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study. Cardiovasc Diabetol (2014) 0.83
The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol (2015) 0.80
Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study. Diabetol Metab Syndr (2014) 0.78
Myocardial capillary density in normal and diabetic male rats: Effect of bezafibrate. Res Pharm Sci (2013) 0.75
Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). Eur J Clin Pharmacol (2011) 0.75
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J (2004) 7.84
Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation (2003) 5.20
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62
A randomized trial of colchicine for acute pericarditis. N Engl J Med (2013) 3.60
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40
Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol (2009) 3.36
COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J (2010) 3.02
Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium. Circulation (2007) 2.99
Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells. Circulation (2009) 2.83
Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts. Circulation (2005) 2.55
Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur Heart J (2005) 2.47
Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation (2011) 2.42
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med (2005) 2.22
The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat (2007) 2.17
Is immigration associated with an increase in risk factors and mortality among coronary artery disease patients? A cohort study of 13,742 patients. Isr Med Assoc J (2002) 2.13
Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis. J Cardiovasc Med (Hagerstown) (2014) 2.12
Functional class in patients with heart failure is associated with the development of diabetes. Am J Med (2003) 2.10
Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. J Am Coll Cardiol (2003) 2.06
Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation (2008) 2.03
Efficacy of omega-3 fatty acid supplementation in primary and secondary prevention of coronary heart disease. Isr Med Assoc J (2004) 2.02
Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J (2006) 2.00
Long-term changes in serum cholesterol level does not influence the progression of coronary calcification. Int J Cardiol (2010) 1.99
Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat (2005) 1.94
Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proc Natl Acad Sci U S A (2009) 1.91
Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med (2011) 1.86
Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. J Am Coll Cardiol (2013) 1.82
Long-term prognostic significance of left atrial volume in acute myocardial infarction. J Am Coll Cardiol (2004) 1.76
Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort. Stroke (2002) 1.70
Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology (2006) 1.65
Mortality and predictors of death 1 month and 3 years after first-ever ischemic stroke: data from the first national acute stroke Israeli survey (NASIS 2004). Neuroepidemiology (2009) 1.64
Perceptual, social, and behavioral factors associated with delays in seeking medical care in patients with symptoms of acute stroke. Stroke (2006) 1.63
Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. JACC Cardiovasc Interv (2008) 1.63
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol (2005) 1.61
Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology (2009) 1.61
Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Natl Acad Sci U S A (2011) 1.58
Monocyte and/or macrophage infiltration of heart after myocardial infarction: MR imaging by using T1-shortening liposomes. Radiology (2012) 1.58
Coronary calcium by spiral computed tomography predicts cardiovascular events in high-risk hypertensive patients. J Hypertens (2004) 1.57
Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood (2008) 1.57
Ischemic stroke on awakening: patients' characteristics, outcomes and potential for reperfusion therapy. Neuroepidemiology (2012) 1.55
Effect of bundle branch block patterns on mortality in hospitalized patients with heart failure. Am J Cardiol (2008) 1.53
Prognosis of myopericarditis as determined from previously published reports. J Cardiovasc Med (Hagerstown) (2014) 1.52
Second-hand tobacco smoke in never smokers is a significant risk factor for coronary artery calcification. JACC Cardiovasc Imaging (2013) 1.52
Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol (2007) 1.50
Deformation dynamics and mechanical properties of the aortic annulus by 4-dimensional computed tomography: insights into the functional anatomy of the aortic valve complex and implications for transcatheter aortic valve therapy. J Am Coll Cardiol (2012) 1.49
Takotsubo syndrome after cardiac surgery. Ann Thorac Surg (2008) 1.49
Relation of body mass index to mortality among men with coronary heart disease. Am J Cardiol (2010) 1.49
Management of pericardial effusion. Eur Heart J (2012) 1.48
Mitral valve enlargement in chronic aortic regurgitation as a compensatory mechanism to prevent functional mitral regurgitation in the dilated left ventricle. J Am Coll Cardiol (2013) 1.48
Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med (2006) 1.46
Pheochromocytoma: cyclic attacks of hypertension alternating with hypotension. Nat Clin Pract Cardiovasc Med (2008) 1.45
Calcification of the thoracic aorta as detected by spiral computed tomography among stable angina pectoris patients: association with cardiovascular events and death. Circulation (2008) 1.45
Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction? Am J Cardiol (2006) 1.44
Exaggerated blood pressure response to exercise is not associated with masked hypertension in patients with high normal blood pressure levels. J Clin Hypertens (Greenwich) (2014) 1.43
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation (2004) 1.42